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1. Introduction 
Organ and tissue transplantations (including blood transfusions) are a critical care 
component for many life-threatening diseases. In transfusion and transplantation medicine, 
the concept of “self” is of crucial importance. Immunological “self” in transfusion medicine 
is primarily mediated by the ABO/RhD blood group antigens, though several hundred 
blood groups exist that can cause problems especially in the chronically transfused patient. 
For most other tissues, “self” is imparted by the major histocompatibility complex (MHC) 
proteins which provide a means for identifying, targeting and eliminating foreign 
(allorecognition) or diseased cells while preserving normal tissue. If the differences between 
donor and recipient occur only at minor MHC molecules (or non-ABO blood group 
antigens) or the transplanted antigens are only weakly antigenic or immunogenic, successful 
engraftment may result. In contrast, if significant differences in the exceedingly 
polymorphic MHC loci are present, or other highly antigenic (e.g., ABO) or immunogenic 
antigens are present, allorecognition of the donor tissue occurs leading to rejection. 
Importantly, while rejection may be manifested as either Host versus Graft or Graft versus 
Host Disease (HVGD and GVHD, respectively), both are mediated by T lymphocyte (T cell) 
activation, differentiation and proliferation consequent to allorecognition. [Cote et al., 2001] 
In this chapter, we will demonstrate how we have utilized flow cytometry to measure the 
induction of tolerance and/or anergy by polymer-mediated immunocamouflage using in 
vitro and in vivo models of allorecognition. 
2. Allorecognition and allorejection 
In HVGD, the host (i.e., recipient) immune system recognizes (allorecognition) and rejects 
the allograft.[Li et al., 2011, Dallman, 2001, Suthanthiran & Strom, 1995] Three major patterns 
of rejection can be identified based on the rapidity of graft injury: hyperacute (minutes to 
hours), acute (days to weeks) and chronic (weeks to years). [Goldstein, 2011, Battaglia, 2010, 
Weigt et al., 2010] In hyperacute rejection not all parts of the graft are actively attacked. The 
primary site of injury is typically the vascular endothelium which can exhibit the ABO blood 
group antigens as well as MHC class I antigens. Damage is initiated by the binding of 
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complement fixing antibodies, complement activation, platelet aggregation, graft 
thrombosis, lytic damage, release of pro-inflammatory complement components (C3a and 
C5a) and leukocyte recruitment. These events result in the microvascular occlusion and the 
rapid loss of graft viability. Because hyperacute rejection occurs rapidly, few if any effective 
therapies for its prevention currently exist. Thus, many patients cannot be transplanted due 
to ABO-incompatibility or the presence of preformed anti-HLA antibodies. In contrast to 
hyperacute rejection, acute and chronic rejection are primarily cell mediated and initiated by 
T cell activation in context of mismatched MHC. Because of its central role, T cells have been 
the traditional focus of immunosuppressive drugs such as cyclosporin A. [Abadja et al., 
2009, Bonnotte et al., 1996, Noris et al., 2007] 
GVHD is, essentially, a special category of HVGD.[Devetten & Vose, 2004] In GVHD, 
immunologically competent T cells, or their precursors, are transfused or transplanted into 
immunocompromised recipients. GVHD occurs most commonly in the setting of allogeneic 
bone marrow transplantation, but may also follow transfusion of whole blood into 
immunocompromised individuals and even some immunocompetent individuals. 
[Kleinman et al., 2003] While both CD4+ (helper) and CD8+ (cytotoxic) T cells play a role in 
mediating tissue rejection in HVGD and GVHD, previous studies have found that depletion 
of MHC class II-recognizing CD4+ T cells to be most effective in preventing rejection.[Noris 
et al., 2007] The MHC disparity between the donor and recipient induces the direct 
activation, differentiation and proliferation of either the recipient’s (HVGD) or donor 
(GVHD) naïve T cells into effector subsets. Moreover, with regards to GVHD, surprisingly 
few T cells are necessary to induce a fatal outcome. Animal models suggest that as few as 
107 donor lymphocytes/kg of recipient weight are sufficient to induce GVHD; though the 
degree of host immunosuppression and the overall disparity of the HLA antigens will exert 
a significant effect on the probability of GVHD induction. 
The risk of donor tissue rejection (and to a lesser extent GVHD) has severely impacted the 
advancement of transplantation medicine. To counter these risks, pharmacologic interventions 
have been employed. Indeed, over the last 40 years, the significant improvements in 
transplantation success have been achieved primarily through immunosuppressive drugs 
that attenuate chronic tissue rejection. Because of the central importance of the T cell in graft 
rejection, thes pharmacological approaches have almost exclusively targeted T cell 
activation or proliferation (Figure 1A). [Allison, 2000] Perhaps the most prominent of these 
drugs has been cyclosporin, which blocks activation of resting T cells by inhibiting the 
signaling pathway necessary for the transcription of interleukin (IL)-2 and the high affinity 
IL-2 receptor. As a consequence, production of both IL-2 and its receptor are significantly 
diminished, thus removing the autocrine and paracrine stimulation necessary for T cell 
proliferation. Unfortunately, these drugs are nondiscriminatory and target not only the 
alloreactive, but all T cell proliferation leading to the induction of a general, non-selective, 
immunosuppressive state that is linked to both a chronic susceptibility to infective agents 
and an increased cancer risk. Moreover, even with pharmacologic intervention, long-term 
graft (as well as patient) survival is often problematic. In part, graft failure is a side effect of 
the immunosuppressive therapy as current pharmacologic agents exert both organ specific 
and systemic toxicity.  
Hence, both HVGD and GVHD are T cell-mediated events that require antigenic recognition 
of the foreign tissue and the elicitation of a T cell-mediated immune response. These effector  
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Fig. 1. Immune modulation via pharmacologic and immunocamouflage therapy. Panel A: 
Current pharmacologic therapy almost exclusively targets T cell activation and proliferation 
consequent to allorecognition. Response to non-self is in large part mediated by cell-cell 
interactions between Antigen Presenting Cells (APC; e.g., dendritic cells) and naïve T cells. 
This cell-cell interaction is characterized by essential adhesion, allorecognition and co-
stimulation events. Consequent to allorecognition, a proliferation of pro-inflammatory T 
cells (e.g., CTL, Th17, Th1 populations) and decrease in regulatory T cells (Treg) is observed. 
Current therapeutic agents are primarily cytotoxic agents preventing T cell activation (e.g., 
cyclosporine and rapamycin) or T cell proliferation (e.g., methotrexate, corticosteroids and 
azathioprine). Additionally some blocking antibodies have been investigated. Panel B: In 
contrast, immunocamouflage of donor cells results in the disruption of the essential cell-cell 
interactions decreasing T cell proliferation and altering differentiation patterns (decreased 
Th17 and increased Tregs). In aggregate, these polymer induced changes induces a 
tolerogenic/anergic state both in vitro and in vivo. Size of T cell population denotes increase 
or decrease in number. Size of B cell indicates antibody response. Modified from: Wang et al. 
(2011). [Wang et al., 2011] 
cells arise via differentiation and proliferation of naïve T cells into proinflammatory and 
cytotoxic subsets (e.g., Th17, Th1, CTL). While a number of different approaches to reduce 
the risk of tissue rejection are currently being examined, these strategies are, typically, 
unilaterally targeted to specific components of the allorecipient’s T cell activation/ 
proliferation pathway (Figure 1A). These include blocking monoclonal antibodies directed 
against the TCR, CD4, co-stimulatory ligands and receptors, adhesion molecules, and 
cytokine receptors. Some of these approaches have undergone clinical testing (e.g., Anti-CD3 
monoclonal antibodies) and demonstrated some promising effects. However, concurrent 
with the anti-rejection efficacy, these agents have been plagued by both significant toxicity 
and an inability to adequately eliminate or inhibit reactive T cells. Hence, these approaches  
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are not commonly used at most transplant institutions. Clinical trials have also tested the 
use of pharmacological inhibitors of T cell proliferation and differentiation. Antiproliferative 
agents such as azathioprine and methotrexate interfere with cellular functions by limiting 
the metabolites necessary for DNA synthesis (Figure 1). However, these compounds also 
demonstrate significant toxicity to organs characterized by high proliferation rates (e.g., 
gastrointestinal tract) and/or drug metabolism (liver), thus limiting their practical 
application. 
Consequently, novel approaches that effectively attenuate the risk of HVGD/GVHD and 
directly target the difficult challenges of the inherent antigenicity and immunogenicity of 
human (and possibly xenogeneic) donor tissues would be of significant value to 
transplantation medicine. Biologically, the most attractive strategy to improve donor tissue 
engraftment and to simultaneously reduce drug toxicity, would be to induce immune 
tolerance and/or anergy in the recipient’s immune system thereby negating the need for 
toxic immunosuppressive pharmacologic agents. Tolerance may be viewed as a relatively 
specific non-responsiveness to a unique antigen while anergy is a more broad-spectrum 
attenuation of the immune response. As with cell-mediated rejection, tolerance and anergy 
are also mediated by a T cells subset (T regulatory cells; Tregs). [Muller et al., 2011]  
3. Immunocamouflage: Concept and mechanism of action 
To prevent allorecognition and alloimmunization, our laboratory has pioneered the 
‘immunocamouflage’ of donor cells and tissues (Figure 1B). [Bradley et al., 2002, Bradley & 
Scott, 2004, Chen & Scott, 2001, Chen & Scott, 2003, Le & Scott, 2010, McCoy & Scott, 2005, 
Murad et al., 1999a, Murad et al., 1999b, Rossi et al., 2010a, Rossi et al., 2010b, Scott et al., 2003, 
Scott et al., 1997, Sutton & Scott, 2010] The immunocamouflage of cells and tissues is created 
by the covalent grafting of safe, non-toxic and low-immunogenic biocompatible polymers 
such as methoxypoly(ethylene glycol, PEGylation) and hyperbranched polyglycerols (HPG) 
to the surface of cells. The efficacy of immunocamouflage is dependent upon both the 
density and depth (i.e., thickness) of the polymer layer. As shown in Figure 2, a rigid linear 
molecules lacks any significant radius of gyration (Rg; space filling) resulting in a poor or 
absent camouflaging (a,b) of the membrane antigens. In contrast, polymers with either high 
intra-chain flexibility (e.g., methoxypoly(ethylene glycol); mPEG; c,d) or inherent density 
(e.g., hyperbranched polyglycerols; HPG; e) exhibit either a significant radius of gyration 
(mPEG) or space filling capacity (HPG). Thus, while mPEG is a linear molecule, its high 
degree of intra-chain flexibility (due to the repeating, highly mobile, ethoxy units) gives rise 
to its expansive Rg. Moreover, due to its hydroscopic nature, the heavily hydrated polymer 
is able to sterically occlude a large three dimensional volume (Figure 2). Consequent to the 
space filling capacity of mPEG, the immunocamouflage of surface membrane proteins and 
carbohydrates (potential antigenic sites) occurs. In addition, the mPEG coating obscures the 
inherent electrical charge associated with surface proteins since the charged molecules 
become buried beneath the viscous, hydrated, neutral PEG layer thus further diminishing 
the antigenic/immunologic character of the cell surface. [Bradley et al., 2002, Bradley & 
Scott, 2004, Le & Scott, 2010] As denoted in Figure 2, the longer the mPEG polymer chain the 
larger the membrane surface area covered by this steric shield (c, d and stippled area). In 
contrast to the flexible linear mPEG, HPG molecules are highly branched structures that 
exhibit limited flexibility but, due to its extensive branching, create a dense steric shield 
(Figure 2e). [Rossi et al., 2010a, Rossi et al., 2010b] 
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Fig. 2. Immunocamouflage of cells is produced via the grafting of polymers to membrane 
proteins. The linear flexible molecule and branched, semi-flexible, grafted polymers creates 
a steric barrier preventing the approach and binding of proteins (e.g., antibodies) and cells 
(e.g., APC or T cells) but along for metabolite (dashed arrows; e.g., glucose) uptake. In 
contrast, rigid linear polymers produce a minimal steric barrier. Some polymers, such as 
mPEG, also very effectively camouflage membrane surface charge. Result present in this 
chapter all refer to methoxy(polyethylene glycol) [mPEG], a linear flexible polymer (c, d). 
L=polymer length as denoted by molecular weight while Rg is the radius of gyration 
 
Fig. 3. Immuno-camouflage of murine RBC with mPEG (SVAmPEG; 20 kDa) results in 
normal in vivo survival. Donor RBC survival was measured via flow cytometry and 
detection of a fluorescent marker (PKH-26) inserted into the RBC membrane via a lipid tail. 
The theoretical effect of the production of anti-mPEG antibodies is shown by the red dashed 
line representing a tertiary transfusion of modified RBC 
Previous studies in our laboratory on red blood cells, lymphocytes, pancreatic islets and 
viral models have demonstrated that the immunocamouflage of tissues is effective, 
reproducible and does not impair tissue function. [Bradley et al., 2002, Bradley & Scott, 2004, 
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Chen & Scott, 2001, Chen & Scott, 2003, Le & Scott, 2010, McCoy & Scott, 2005, Murad et al., 
1999a, Murad et al., 1999b, Rossi et al., 2010a, Rossi et al., 2010b, Scott et al., 2003, Scott et al., 
1997, Sutton & Scott, 2010] For example, the PEGylated red blood cell function (i.e., O2 
delivery and cellular deformability) were unaffected by the grafted polymer and exhibited 
normal in vivo circulation and lifespan (~50 day) in a murine transfusion model even after 
repeated transfusions (Figure 3). With relevance to tissue transplantation, our studies have 
demonstrated that transfusion of immunocamouflaged allogeneic murine splenocytes 
prevents allorecognition by either the donor cells (e.g., Transfusion-Associated Graft vs. 
Host Disease model) or the recipients (e.g., graft rejection model) immune system. [Chen & 
Scott 2003, Chen & Scott 2006] The loss of allorecognition is not accompanied by any 
systemic or local toxicity. More surprisingly, recent adoptive transfer studies within our 
laboratory using a murine model have demonstrated that immunocamouflaged leukocytes 
may be able to induce long-lasting systemic immunotolerance. [Wang et al., 2011] An 
important and exceptionally powerful tool in assessing the efficacy of immunocamouflage 
in both in vitro and in vivo modeling systems has been flow cytometry. 
4. Assessing polymer-mediated immunomodulation by flow cytometry: T cell 
camouflage, differentiation and proliferation 
Flow cytometry is essential in characterizing both in vitro and in vivo immunological 
response including cell proliferation (CSFE staining and murine H2 determination), 
cytokine expression (cytometric bead array), intra-cellular signaling cascades, lymphocyte 
differentiation (e.g., Tregs and Th17 cells) and in vivo cell trafficking (e.g., thymus, spleen, 
lymph node and blood). Indeed, as will be shown in this chapter, flow cytometry is an 
exceptionally powerful tool in investigating the induction of tolerance and/or anergy in 
experimental models. 
Mechanistically, allorecognition requires multiple sustained interactions between the donor 
and recipient tissues for the activation, differentiation and proliferation of alloresponsive T 
cell to occur. These interactions, involving both external receptor-ligand interactions and 
intracellular signalling cascades fall within three general categories: 1) cell:cell adhesion 
events; 2) allorecognition; and 3) costimulation. [Chen & Scott, 2001, Murad et al., 1999a] 
Blockade or attenuation of any (or all) of these events will reduce allorecognition and 
allograft rejection. The in vitro and in vivo effects of polymer-mediated immunocamouflage 
on these essential events are readily measured via flow cytometry.  
4.1 Immunocamouflage of membrane markers 
Multiple receptor-ligand interactions (encompassing adhesion, allorecognition and 
costimulation pathways) between the T cell and APC are essential for successful 
allostimulation. The membrane proteins involved in these cell:cell events have been well 
characterized over the last several years and often targeted by experimental therapies. 
Importantly, the efficacy of immunocamouflage can be readily assessed by the literal 
camouflage of these markers using flow cytometry. 
Previously, we investigated the efficacy of immunocamouflage in a murine model of 
transfusion-associated graft versus host disease (TA-GVHD). [Chen & Scott, 2003, Chen & 
Scott, 2006] Using this model, flow cytometric analysis demonstrated that polymer grafting  
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significantly camouflaged membrane proteins involved in adhesion, allorecognition and co-
stimulation events. As shown in Table 1, the immunocamouflage of allogeneic donor 
lymphocytes resulted in the efficient camouflage of donor leukocyte membrane markers. 
These membrane proteins are still present on the surface of the allogeneic leukocytes but are 
camouflaged by the grafted polymer from detection by anti-marker antibodies. Consequent 
to the polymer-mediated camouflage, signal transduction is block or significantly 
attenuated.  
mM 
mPEG 
Polymer 
m.w.
CD3ε T cell 
receptor
CD11a MHC 
Class II
CD4 CD25 CD28 
0 - 100% 100% 100% 100% 100% 100% 100% 
0.6 5 kDa 59* 20* 49* 100 75 ND 64* 
 20 kDa 73* 14* 53* 100 84 67* 35* 
1.2 5 kDa 53* 11* 39* 100 65* 62* 31* 
 20 kDa 27* 2* 26* 45* 53* 67* 30* 
2.4 5 kDa 38* 7* 30* 59* 7* 12* 31* 
 20 kDa 3* 5* 7* 8* 3* 67* 40* 
Table 1. The covalent grafting of mPEG to membrane proteins results in the global 
camouflage of multiple proteins crucial for effective allorecognition of foreign tissue. Values 
shown are “Percent Positive Cells” relative to the unmodified control (=100%). Results 
shown are the mean of a minimum of 3 independent experiments. * p < 0.01 compared to 
unmodified controls 
4.2 Effect of immunocamouflage on cytokine-chemokine release 
Consequent to the camouflage of the receptor-ligands necessary for alloresponsiveness, a 
dramatic reduction in cytokine/chemokine release is observed. Flow cytometry provides a 
valuable tool for the simultaneous measurement of cytokine (signalling molecules integral 
to the immune response) production, T cell proliferation and differentiation. Historically, 
cytokines were commonly measured using enzyme-linked immunosorbent assays (ELISA or 
EIA); a relatively low throughput system. Flow cytometry has greatly increased both the 
speed and sensitivity of cytokine measurements both in vitro and in vivo. One of the most 
powerful flow cytometric tools in this regard is the BD™ Cytometric Bead Array (CBA; 
BD™ Biosciences, San Diego, CA). There are significant advantages for using the CBA 
versus ELISA. The CBA Array system is a multiplex quantitive assay requiring fewer 
sample dilutions and utilizing a single set of standards to generate a standard curve for each 
analyte. Moreover, the throughput of the CBA is significantly greater than ELISA (e.g., 1/2 
day for the CBA Array versus 2-3 days for ELISA). 
The CBA system is a multiplexed bead based immunoassay used to simultaneously quantitate 
multiple soluble cytokines within a single sample by fluorescence-based emission. This 
assay allows multiple simultaneous cytokine determinations in serum, plasma, cell lysates 
or tissue culture supernatants. As shown in Figure 4, each sample preparation can contain 
multiple bead populations, each with distinct fluorescence intensity. Each of these bead 
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populations (capture beads) are coated with an antibody for a specific cytokine and 
essentially mimics an individually coated well in an ELISA plate. The capture beads are 
mixed with the sample of interest (standard or experimental sample) and a PE-conjugated 
detection antibody to form a sandwich complex and resolved using the FL3 or FL4 channel. 
The data is analyzed using specific software (FCAP Array™ and BD CBA™ analysis 
software; BD Biosicences, San Diego, CA and Soft Flow Inc, St. Louis Park, MN) to provide a 
quantitative value for the selected cytokines.  
 
Fig. 4. Quantitative Cytometric Bead Array™. Capture beads are conjugated to analyte 
specific antibodies (e.g., anti-Il-2, Il-17, INF-γ or TNF-α as shown). Each bead has a different 
fluorescent intensity allowing for analyate discrimination 
For our experiments, a BD™ CBA Human Th1/Th2 Cytokine Kit (Catalog No. 550749) and 
Murine Th1/Th2 Cytokine Kit (Catalog No. 551287) were utilized to determine the effects of 
immunocamouflage on allorecognition in vitro and in vivo. For in vitro human or mouse 
studies, cell culture supernatants were collected and stored at -80°C prior to analysis. For 
flow cytometric analysis samples were incubated with desired detection kit (e.g., Th1/Th2) 
capture beads and a PE-conjugated detection antibody and aquired using a BD 
FACSCaliburTM flow cytometer and the Cell Quest Pro Software. Cytokine protein levels 
were analyzed using the BD™ Cytometric Bead Array and FCAP Array™ analysis software 
(BD Biosicences, San Diego, CA and Soft Flow Inc, St. Louis Park, MN). 
As demonstrated in Figure 5, resting human PBMC, as well as resting PEGylated PBMC, 
expressed little detectable IL-2, TNF-α or INF-γ. [Wang et al., 2011] However, when two 
disparate populations (two-way mixed lymphocyte reaction; 2-way MLR) of PBMC are 
mixed together, allorecognition occurs resulting in very significant increases in these 
cytokines. In stark contrast to the positive control MLR, the PEGylation of either donor 
population results in an immunoquiescent state characterized by baseline (i.e., resting 
PBMC) levels of these cytokines. Also shown in Figure 5 is a diagrammatic presentation of 
how the capture beads detect cytokine levels of the control and PEGylated MLR.  
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Fig. 5. Effect of immunocamouflage on cytokine secretion as measured by flow cytometry 
using the BD Cytometric Bead Array™ (CBA). Also shown is a diagrammatic representation 
of the capture beads and bound analayte for the control 2-way MLR and mPEG 2-way MLR. 
Modified from Wang et al. (2011). [Wang et al., 2011] 
4.3 Effect of immunocamouflage on In Vitro and In Vivo T cell proliferation and 
differentiation 
For decades, 3H-thymidine incorporation was the standard for measuring cell proliferation 
in MLRs. While highly useful in vitro, this methodology is less useful in vivo. Moreover, 
radionucleotides bring additional regulatory burden to research laboratories. Hence, 
alternative approaches for measuring proliferation have been developed. Multiple flow 
cytometric tools are available for this purpose. Perhaps the most common of these flow 
methodologies is a dye dilution assay utilizing carboxyfluorescein succinimidyl ester 
(CFSE). Importantly, the CFSE assay is a valuable tool for both in vitro and in vivo 
proliferation assays. 
CFSE was originally developed to label lymphocytes and track their in vivo migration over 
several months. [Weston & Parish, 1990] Subsequent studies demonstrated its utility in 
measuring lymphocyte proliferation both in vitro and in vivo consequent to the progressive 
dilution of CFSE fluorescence within daughter cells following each cell division. For cell 
staining, carboxyfluorescein diacetate succinimidyl ester (CFDA-SE; a non-fluorescent 
precursor to CFSE), a highly cell permeable compound, is added to a cell population (e.g., 
human PBMC or murine splenocytes) where it enters the cytoplasm of cells. Within the cell, 
intracellular esterases remove the acetate groups present on CFDA-SE and convert the 
molecule to the fluorescent ester, CFSE. The CFSE molecule is permanently retained within 
cells due to its covalent coupling to intracellular molecules via its succinimidyl group. The 
CSFE signal is extremely stable allowing for long-term studies and is not transferred to 
adjacent cells. However, upon allostimulation (or mitogen challenge) and proliferation, the 
CFSE dye is evenly diluted between the daughter cells and continues to be diluted with 
subsequent proliferation of these cells (Figure 6). With optimal labelling, 7-8 cell divisions 
can be identified before the CFSE fluorescence is indistinguishable from backgound 
autofluorescence. Thus, this assay thereby provides significant quantitative data as to the 
percentage of alloresponsive cells within a population as well as the degree of proliferation 
over a course of several days to weeks. 
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Fig. 6. Flow cytometric analysis of intracellular CFSE can be used to measure cell 
proliferation based on dye-dilution within the daughter cells (0-4). CFSE can be used both in 
vitro and in vivo where it can also be used to investigate cell trafficking. The grey peak 
represents unlabeled cells 
 
Fig. 7. Proliferation of CD4+ T cells in resting PBMC (A), Control MLR (B) and mPEG-MLR 
(C). Denoted in B are the proliferation (1-4) peaks of the alloresponsive subpopulation. 
Shown is the flow cytometric analysis of a representative experiment of human PBMC 
The ultimate efficacy of immunocamouflage of allogeneic cells in MLRs is primarily 
assessed by the loss of proliferation. As shown in Figure 7, polymer grafting to either 
immunologically disparate population results in the loss of cell proliferation. [Wang et al., 
2011] Importantly, this is not due to any loss of viability of the polymer modified cells as 
direct mitogen stimulation yields normal nearly identical proliferation rates as unmodified 
cells (as measured by CFSE or 3H-thymidine incorporation; not shown). The loss of 
proliferation is consequent to the global immunocamouflage of the receptor-ligand markers 
described in Table 1.  
In vivo cell trafficking of allogeneic donor cells is also of importance in immunological 
studies. While this can be done using radiolabelled cells, it is a low resolution assay and is 
often quantitated as simply CPM per organ. In contrast, flow cytometry can provide 
significantly improved information. In murine studies it is possible to look at the 
proliferation of allogeneic donor cells based on flow cytometric analysis of the murine 
haplotype (H2). In an in vivo murine model of transfusion associated graft versus host 
disease (TA-GVHD) in which mice are transfused with allogeneic cells, significant 
proliferation of the donor cells is observed in lymphatic tissues such as the spleen after 28  
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days (Figure 8). [Chen & Scott, 2003, Chen & Scott, 2006] In contrast, if the allogeneic donor 
cells are PEGylated prior to their transfusion, minimal allorecognition of the foreign host 
tissues occurs and there is no significant proliferation of the donor splenocytes (Figure 8). 
While not shown, CFSE labelling can also be an important flow cytometric tool for 
simultaneously monitoring the trafficking and proliferation of donor cells in vivo. Both H2 
markers and/or CSFE can be further coupled with the use of fluorescent antibodies against 
lymphocyte cell surface markers (e.g., CD4, CD25, IL-17R, etc.) making it possible to follow 
in vivo lymphocyte differentiation. Due to the non-toxic nature of CFSE, labelled viable cells 
can be recovered via cell flow cytometric cell sorting for further in vitro analysis. 
 
Fig. 8. Immunocompetent Balb/c mice (H2Kd) were transfused with 1.5 x 107 unmodified or 
mPEG-modified C57Bl/6 splenocytes (H2Kb) on days 0 and 14. At day 28, mice were 
sacrificed and the in vivo donor cell proliferation was assessed by flow cytometry using an 
anti-H2Kb monoclonal antibody. Shown are the mean precent donor cells within the spleens 
of the recipient animals (n=4/group) 
Differentiation of naïve T cells is an important regulator of the immune response or lack of 
response. [Heidt et al., 2010, Nistala & Wedderburn, 2009, O'Gorman et al., 2009, Oukka, 
2007] As our understanding of the biological functions of T cells has expanded a vast array 
of T cell subsets, all of which have unique immunological functions and phenotypes, have 
been described. Indeed, T cell differentiation is a crucial indicator of whether an inflammatory 
or tolerogeneic response is induced consequent to exposure to control or polymer-modified 
allogeneic tissue. Fortunately, flow cytometry provides a high throughput tool for the 
analysis of T cell differentiation. 
Consequent to the immunocamouflage of the receptor-ligands involved in adhesion, 
allorecognition and costimulation (see Table 1) T cell activation and proliferation was 
significantly attenuated (see Figures 7-8). However, these findings did not elucidate if there 
was a differential proliferation effect between T cell subsets. Hence, flow cytometric T cell 
subset phenotyping was used to further investigate the effects of immunocamouflage on T 
cell differentiation both in vitro and in vivo. [Afzali et al., 2007, Hanidziar & Koulmanda, 
2010, Heidt et al., 2010, Mitchell et al., 2009, Weaver & Hatton, 2009] For example, as shown 
in Figure 9, in vivo challenge with unmodified allogeneic cells results in the upregulation of 
proinflammatory Th17 cells and a downregulation of immunosuppressive Treg cells within 
the spleen as determined by flow cytometry. [Wang et al., 2011] In contrast, the 
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immunocamouflage of the allogeneic cells resulted in increased Treg cells significantly 
above that of naïve mice and a virtually complete abrogation of the expected Th17 increase. 
Importantly, soluble polymer as well as unmodified or mPEG-modified syngeneic cells 
demonstrated no effects on the in vivo differentiation of Treg or Th17 cells. Similar finding in 
the lymph nodes and blood were observed. Indeed, as summarized in Figure 10, the 
immunocamouflage of allogeneic human (in vitro) and mouse (in vitro and in vivo) 
leukocytes has been experimentally shown to dramatically influence T cell differentiation 
resulting in the induction and persistence of a tolerogeneic/anergic state. [Chen & Scott, 
2003, Chen & Scott, 2006, Wang et al., 2011]  
 
Fig. 9. Flow cytometric studies demonstrate that immunocamouflage of allogeneic murine 
splencoytes alters the in vivo systemic differentiation of Th17 and Treg lymphocytes. Shown 
are the percent Th17 and Treg CD4+ lymphocytes within the spleen of animals transfused 
with control or mPEG allogeneic splencocytes. Similar finding in the lymph nodes and 
blood were observed. Grey bars denote baseline levels of Th17 and Treg cells in naïve 
animals. The ∆d (yellow area) denotes the absolute difference between unmodified and 
mPEG-modified allogeneic splenocytes Derived from Wang, Chen and Scott (2011) 
T cell subset differentiation is driven by variable intracellular signaling cascades triggered 
by the adhesion, allorecognition, costimulatory and cytokine receptor-ligand interactions 
occurring at the membrane of the naïve T cell. In the case of immunosuppressive Treg cells 
and the proinflammatory Th17 cells, the key nuclear transcription factors FoxP3+ and 
RORγ+, respectively, are used to detect these cell types via flow cytometry. Moreover, these 
markers can be combined with Phosflow™ assays to provide additional activation 
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information. [Krutzik et al., 2004] This technique combines flow cytometric analysis of 
phosphospecific antibodies with, for example, lymphocyte subtyping allowing for more 
specific identification of activated cell types. Phosphospecific antibodies are specific to 
tyrosine or serine phosphorylated signaling intermediates, thus antibody will only bind to a 
protein in its phosphorylated state. Since phosphorylation is a key mechanism of regulation 
in signaling pathways, this methodology enables the studies of a vast number of pathways 
in a variety of cells. This technology provides significantly enhanced resolution relative to 
western blots or ELISAs that only assess the overall activity of an entire population and that 
do not allow for easy isolation or phenotypic identification of the alloreactive cells involved. 
 
Fig. 10. Flow cytometric analysis of T cell differentiation both in vitro and in vivo 
demonstrates the polymer grafting to allogeneic leukocytes significantly influences the 
differentiation of naïve T cells. As shown diagrammatically above, immunocamouflage of 
allogeneic cells favors tolerogeneic/anergic T cell subsets and significantly inhibits 
proinflammatory T cell populations. Lymphocyte abbreviations: NK, natural killer; CTL, 
cytotoxic; Mem, memory; and Exh, exhausted (TCR-) T cells 
For example, as illustrated in Figure 11, initiation of differentiation of the Th17 T cell lineage 
is controlled by the master regulatory transcription factor RORγ. This transcription factor is 
upregulated in response to IL-6 and TGF-β that, together with the T cell receptor (TCR) 
signal, initiate differentiation of Th17 from naive T cells via the Gp130-STAT3 pathways. 
[Kitabayashi et al., 2010, Nishihara et al., 2007] Il-6 acts directly to promote the development 
of Th17 by binding to the membrane IL-6 receptor of T cells and its signal transducer protein 
Gp130. Binding of the cytokine induces activation (phosphorylation) of Jaks which serve as 
a docking site for STAT3. STAT3 is then phosphorylated by Jak inducing its dimerization, 
nuclear translocation and DNA binding. To assess the activation of this pathway consequent 
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to mitogen or allostimulation, cells can be fixed, permeabilized and stained for 
phosphospecific (Tyr705) STAT3 and analyzed via flow cytometry.  
 
Fig. 11. Phosphospecific flow cytometry can measure the phosphorylation state of 
intracellular proteins at the single cell level. Many different phosphorylation states can be 
measured simultaneously in each cell, along with other intracellular (e.g., IL-17A) and/or 
surface (e.g., CD4) markers, enabling complex signaling networks to be resolved. Phosflow 
assays are performed by stimulating cells, fixing and permeabilizing before staining with 
phosphospecific fluorophore conjugated antibody for flow cytometric analysis 
Thus, by using the wide variety of flow cytometric tools available, it is possible to detect 
changes within a small subpopulation of a heterogenous cell population without need to go 
through expensive cell sorting or purification steps. Finally, powerful analysis can be done 
using multiple parameter flow cytometer staining. However, timing of phosphorylation 
events with membrane surface phenotype expression, gene transcription and cytokine 
release still pose a significant challenge in the utilization of the Phosflow™ technology. 
5. Conclusion 
Flow cytometry has assumed an increasingly important role in the diagnosis and 
monitoring of disease progression or regression in modern medicine.[Chesney et al., 2011, 
Dieterlen et al., 2011, Hedley et al., 2011, Hernandez-Fuentes & Salama, 2006, Mittag & 
Tarnok, 2011, Panzer & Jilma, 2011, Tung et al., 2007, Venet et al., 2011] Indeed, flow 
cytometry has proved to be an exceptionally powerful tool in assessing the rejection or 
acceptance of allogeneic tissues. Flow cytometry is essential in characterizing both in vitro 
and in vivo immunological response including cell proliferation (CSFE staining and murine 
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H2 determination), cytokine expression (cytometric bead array), intra-cellular signaling 
cascades, lymphocyte differentiation (e.g., Tregs and Th17 cells) and in vivo cell trafficking 
(e.g., thymus, spleen, lymph node and blood). Moreover, the flow cytometry tools available 
for immunological studies continue to expand thereby enhancing our ability to decipher the 
immune response to non-self antigens. By using the unique tools provided by flow 
cytometry, our own studies have been better able to elucidate the mechanisms by which the 
polymer-mediated immunocamouflage of allogeneic cells influences T cell differentiation 
(both in vitro and in vivo) to produce a stable tolerogeneic/anergic state. [Chen & Scott, 2003, 
Chen & Scott, 2006, Murad et al., 1999a, Wang et al., 2011]  
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